Status:
UNKNOWN
Unfractioned Heparin for Treatment of Sepsis Caused by Abdominal Infection
Lead Sponsor:
The Third Xiangya Hospital of Central South University
Collaborating Sponsors:
Xiangya Hospital of Central South University
Central South University
Conditions:
Sepsis
Gram-Negative Bacterial Infections
Eligibility:
All Genders
18-75 years
Phase:
PHASE3
Brief Summary
Sepsis is the leading cause of death in intensive care units and a major public health concern in the world. Heparin, a widely used anticoagulant medicine to prevent or treat thrombotic disorders, has...
Detailed Description
In clinical patients, the major pathogens of sepsis caused by abdominal infection are mostly Gram-negative bacterium. Therefore, aim of this study is to determine effects of low dose unfractionated he...
Eligibility Criteria
Inclusion
- Patients will be eligible for inclusion if all of the inclusion criteria are met:
- Sepsis-3 criteria from Society of Critical Care Medicine (SCCM) /European Society of Intensive Care Medicine (ESICM), and the infection site is from abdomen 2.18≤ age ≤75years 3.obtain informed consent
Exclusion
- The primary site of infection is from other parts (such as lungs, intracranial, etc.) except abdomen
- Diagnosis of sepsis for more than 48 hour
- Pregnant and lactating women
- Severe primary disease including unrespectable tumours, blood diseases and Human Immunodeficiency Virus (HIV);
- Have a known or suspected adverse reaction to UFH including HIT
- Have bleeding or high risk for bleeding
- Have an indication for therapeutic anticoagulation or have taken anticoagulants within 7 days
- Use of an immunosuppressant or having an organ transplant within the previous 6 months
- Participating in other clinical trials in the previous 30 days
- Have received cardiopulmonary resuscitation within 7 days
- Have terminal illness with a life expectancy of less than 28 days
Key Trial Info
Start Date :
May 11 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 30 2024
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04861922
Start Date
May 11 2021
End Date
July 30 2024
Last Update
March 21 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The third Xiangya Hospital, Central South University
Changsha, Hunan, China, 410013